MEMORANDUM

APR 30 1987

SUBJECT: Tetramethrin; EPA Reg. No. 10308-1; Addendum to Pathology Report

Caswell No. 844
Record No. 187794
Project No. 7-0359
Accession No. MRID 143555

TO: Paul Schroeder
Product Manager, 17
Registration Division, TS-767

THRU: Edwin Budd, Section Head
Review Section II
Toxicology Branch
Hazard Evaluation Division, TS-769

FROM: William Dykstra
Toxicology Branch
Hazard Evaluation Division, TS-769

3/31/87

Requested Action:

Review addendum to pathology report by Drs. Vesselinovitch and Ito.

Conclusions and Recommendations:

1. The addendum to the pathology report is only acceptable as supplementary information. The addendum presents the summary findings based on the pathologic interpretation of interstitial cell lesions and neoplasms as determined by Sumitomo consultants, Drs. Vesselinovitch and Ito.

It should be noted that the data in the consultants report does not include the histologic details of the individual rats used in the 1974 and 1981 chronic rat studies. TB presently has the details of the individual animal, from the Hazleton studies and will perform survival disparity analyses, life-table analyses, and statistical analyses for presentation to the TB Peer Review Committee.
The pathology addendum also contains the consultant's statistical analysis of the testicular lesions and neoplasms in the three rat studies.

The summary statistical and pathology data presented in the addendum will be presented, along with TB assessments, to the Peer Review Committee.

Review:


A. No new data were presented. The summary incidence data and statistical analyses in the addendum do not impact significantly on the Hazelton evaluation. For future reference, the addendum is attached to the present review.
ADDENDUM TO: HISTOLOGIC EVALUATION AND INTERPRETATION OF
OF NEO-PYNAmin BIOASSAY STUDIES CARRIED OUT ON SPRAGUE-DAWLEY
LABORATORIES INC. FOR SUMITOMO CHEMICAL COMPANY, LTD.
(SEPTEMBER 9, 1982)

BY

S.D. VESSELINOVITCH AND N. ITO

[Signature]

Stan D. Vesselinovitch

July 27, 1984

Date
Page 4 is not included in this copy.
Pages 4 through 23 are not included.

The material not included contains the following type of information:

___ Identity of product inert ingredients.
___ Identity of product impurities.
___ Description of the product manufacturing process.
___ Description of quality control procedures.
___ Identity of the source of product ingredients.
___ Sales or other commercial/financial information.
___ A draft product label.
___ The product confidential statement of formula.
___ Information about a pending registration action.
✓ FIFRA registration data.
___ The document is a duplicate of page(s) ________.
___ The document is not responsive to the request.

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.